CSIMarket
 


Rocket Pharmaceuticals Inc   (RCKT)
Other Ticker:  
 
 

RCKT's Operating Income Growth by Quarter and Year

Rocket Pharmaceuticals Inc 's Operating Income results by quarter and year




RCKT Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -69.08 -44.33 -27.39
III Quarter September -65.43 -58.49 -49.65 -23.56
II Quarter June -68.76 -54.21 -34.05 -24.12
I Quarter March -62.19 -42.56 -39.22 -19.65
FY   -196.38 -224.34 -167.25 -94.72



RCKT Operating Income third quarter 2023 Y/Y Growth Comment
Rocket Pharmaceuticals Inc in the third quarter 2023 recorded Operating Loss of $ -65.43 millions.

According to the results reported in the third quarter 2023, Rocket Pharmaceuticals Inc achieved the best Operating Income growth in Major Pharmaceutical Preparations industry. While Rocket Pharmaceuticals Inc ' s Operating Income no change of % ranks overall at the positon no. in the third quarter 2023.

Explain Operating Income growth


RCKT Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Rocket Pharmaceuticals Inc 's third quarter 2023 Operating Income $ -65.43 millions RCKT's Income Statement
Rocket Pharmaceuticals Inc 's third quarter 2022 Operating Income $ -58.49 millions Quarterly RCKT's Income Statement
New: More RCKT's historic Operating Income Growth >>


RCKT Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Rocket Pharmaceuticals Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RCKT's III. Quarter Q/Q Operating Income Comment
Although Rocket Pharmaceuticals Inc in the III. Quarter 2023 admitted Operating Loss of $ -65.43 millions, some analyst point out, that current results are improvement in contrast to the -68.76 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Rocket Pharmaceuticals Inc achieved highest sequential Operating Income growth. While Rocket Pharmaceuticals Inc 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RCKT's III. Quarter Q/Q Operating Income Comment
Although Rocket Pharmaceuticals Inc in the III. Quarter 2023 showed Operating Loss of $ -65.43 millions, some analyst said, that those numbers are slight up side compare to the -68.76 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Rocket Pharmaceuticals Inc achieved highest sequential Operating Income growth. While Rocket Pharmaceuticals Inc 's Operating Income growth quarter on quarter, overall rank is .


Rocket Pharmaceuticals Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Operating Income 12 Months Ending $ -265.46 $ -258.52 $ -243.97 $ -224.34 $ -199.59
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Rocket Pharmaceuticals Inc ' has realized cumulative trailing twelve months Operating Loss of $ -265 millions in the Sep 30 2023 period.
The situation is getting worse as the cumulative Operating Loss is getting bigger from $ -258.52 millions in the twelve months ending a quarter before and $ -190.752 millions from the TTM period ending Sep 30 2022 Ben  Davies wrote.

Rocket Pharmaceuticals Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Rocket Pharmaceuticals Inc ' has realized cumulative trailing twelve months Operating Loss of $ -265 millions in the Sep 30 2023 period.
The situation is detiriorating as the cumulative Operating Loss is becoming larger from $ -258.52 millions in TTM ending quarter Jun 30 2023 and $ -190.752 millions for the twelve months ending in the quarter a year ago Ben  Davies wrote.

Rocket Pharmaceuticals Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
RCKT's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for RCKT's Competitors
Operating Income Growth for Rocket Pharmaceuticals Inc 's Suppliers
Operating Income Growth for RCKT's Customers

You may also want to know
RCKT's Annual Growth Rates RCKT's Profitability Ratios RCKT's Asset Turnover Ratio RCKT's Dividend Growth
RCKT's Roe RCKT's Valuation Ratios RCKT's Financial Strength Ratios RCKT's Dividend Payout Ratio
RCKT's Roa RCKT's Inventory Turnover Ratio RCKT's Growth Rates RCKT's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2023
Sotera Health Company20.42%$ 20.418 millions
Biomx Inc 19.03%$ 19.026 millions
Shockwave Medical Inc 18.66%$ 18.660 millions
Intuitive Surgical Inc 16.77%$ 16.771 millions
Nature s Sunshine Products inc 16.36%$ 16.361 millions
Align Technology inc 15.79%$ 15.795 millions
Stryker Corp15.22%$ 15.223 millions
Encompass Health Corporation14.02%$ 14.021 millions
Idexx Laboratories Inc12.44%$ 12.439 millions
Envista Holdings Corporation11.81%$ 11.812 millions
Surgery Partners Inc 11.47%$ 11.471 millions
Medpace Holdings Inc 9.10%$ 9.098 millions
Zoetis Inc 9.07%$ 9.066 millions
Zimmer Biomet Holdings Inc 8.68%$ 8.683 millions
Amedisys Inc 8.43%$ 8.425 millions
Hca Healthcare Inc 7.79%$ 7.787 millions
Chemed Corporation7.41%$ 7.412 millions
Ensign Group Inc7.41%$ 7.410 millions
Dariohealth Corp 6.68%$ 6.677 millions
U S Physical Therapy Inc6.62%$ 6.620 millions
Halozyme Therapeutics Inc 5.99%$ 5.987 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com